Bionano Genomics (BNGO) Competitors

$1.24 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.81%)

As of 04:14 PM Eastern

BNGO vs. PRPO, AATC, CLIR, DAIO, and MSAI

Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Precipio (PRPO), Autoscope Technologies (AATC), ClearSign Technologies (CLIR), Data I/O (DAIO), and MultiSensor AI (MSAI). These companies are all part of the "measuring and control equipment" industry.

How does Bionano Genomics compare to Precipio?

Bionano Genomics (NASDAQ:BNGO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

: Bionano Genomics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
: In the previous week, Bionano Genomics had 4 more articles in the media than Precipio. MarketBeat recorded 4 mentions for Bionano Genomics and 0 mentions for Precipio. Bionano Genomics' average media sentiment score of 0.64 beat Precipio's score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.
Company Overall Sentiment
Bionano Genomics Positive
Precipio Neutral
: Precipio has lower revenue, but higher earnings than Bionano Genomics. Precipio is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionano Genomics $28.51M 0.48 -$26.40M -$4.76 N/A
Precipio $24.05M 2.40 -$360K -$0.25 N/A
: Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 383.87%. Given Bionano Genomics' stronger consensus rating and higher possible upside, research analysts plainly believe Bionano Genomics is more favorable than Precipio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionano Genomics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Precipio
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Precipio has a net margin of -1.51% compared to Bionano Genomics' net margin of -92.59%. Precipio's return on equity of -2.78% beat Bionano Genomics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bionano Genomics -92.59% -56.22% -34.38%
Precipio -1.51% -2.78% -1.84%
: 11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 16.9% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Overall Sentiment
Bionano Genomics	Positive
Precipio	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.48	-$26.40M	-$4.76	N/A
Precipio	$24.05M	2.40	-$360K	-$0.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-92.59%	-56.22%	-34.38%
Precipio	-1.51%	-2.78%	-1.84%

Summary

Bionano Genomics beats Precipio on 9 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Autoscope Technologies?

Bionano Genomics (NASDAQ:BNGO) and Autoscope Technologies (NASDAQ:AATC) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

: Bionano Genomics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Autoscope Technologies has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.
: In the previous week, Bionano Genomics had 4 more articles in the media than Autoscope Technologies. MarketBeat recorded 4 mentions for Bionano Genomics and 0 mentions for Autoscope Technologies. Bionano Genomics' average media sentiment score of 0.64 beat Autoscope Technologies' score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.
Company Overall Sentiment
Bionano Genomics Positive
Autoscope Technologies Neutral
: Autoscope Technologies has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionano Genomics $28.51M 0.48 -$26.40M -$4.76 N/A
Autoscope Technologies $12.89M 2.27 $6.62M $0.26 20.42
: Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 383.87%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than Autoscope Technologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionano Genomics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Autoscope Technologies
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -92.59%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bionano Genomics -92.59% -56.22% -34.38%
Autoscope Technologies 37.59% 27.06% 23.97%
: 11.4% of Bionano Genomics shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 21.6% of Autoscope Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Overall Sentiment
Bionano Genomics	Positive
Autoscope Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.48	-$26.40M	-$4.76	N/A
Autoscope Technologies	$12.89M	2.27	$6.62M	$0.26	20.42

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Autoscope Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-92.59%	-56.22%	-34.38%
Autoscope Technologies	37.59%	27.06%	23.97%

Summary

Bionano Genomics and Autoscope Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to ClearSign Technologies?

Bionano Genomics (NASDAQ:BNGO) and ClearSign Technologies (NASDAQ:CLIR) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

: Bionano Genomics has a net margin of -92.59% compared to ClearSign Technologies' net margin of -105.01%. ClearSign Technologies' return on equity of -53.54% beat Bionano Genomics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bionano Genomics -92.59% -56.22% -34.38%
ClearSign Technologies -105.01% -53.54% -40.94%
: Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 383.87%. ClearSign Technologies has a consensus price target of $20.00, indicating a potential upside of 307.33%. Given Bionano Genomics' higher probable upside, analysts plainly believe Bionano Genomics is more favorable than ClearSign Technologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionano Genomics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
ClearSign Technologies
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Bionano Genomics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, ClearSign Technologies has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
: In the previous week, Bionano Genomics had 3 more articles in the media than ClearSign Technologies. MarketBeat recorded 4 mentions for Bionano Genomics and 1 mentions for ClearSign Technologies. ClearSign Technologies' average media sentiment score of 1.45 beat Bionano Genomics' score of 0.64 indicating that ClearSign Technologies is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bionano Genomics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ClearSign Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 24.0% of ClearSign Technologies shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 4.7% of ClearSign Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: ClearSign Technologies has lower revenue, but higher earnings than Bionano Genomics. ClearSign Technologies is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionano Genomics $28.51M 0.48 -$26.40M -$4.76 N/A
ClearSign Technologies $5.23M 5.07 -$5.50M -$1.20 N/A

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-92.59%	-56.22%	-34.38%
ClearSign Technologies	-105.01%	-53.54%	-40.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearSign Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearSign Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.48	-$26.40M	-$4.76	N/A
ClearSign Technologies	$5.23M	5.07	-$5.50M	-$1.20	N/A

Summary

Bionano Genomics and ClearSign Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to Data I/O?

Data I/O (NASDAQ:DAIO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

: Data I/O has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
: Data I/O has a net margin of -23.19% compared to Bionano Genomics' net margin of -92.59%. Data I/O's return on equity of -31.01% beat Bionano Genomics' return on equity.
Company Net Margins Return on Equity Return on Assets
Data I/O -23.19% -31.01% -21.80%
Bionano Genomics -92.59% -56.22% -34.38%
: Data I/O currently has a consensus target price of $5.11, indicating a potential upside of 80.57%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 383.87%. Given Bionano Genomics' higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Data I/O.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Data I/O
2 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.40
Bionano Genomics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Bionano Genomics had 1 more articles in the media than Data I/O. MarketBeat recorded 4 mentions for Bionano Genomics and 3 mentions for Data I/O. Bionano Genomics' average media sentiment score of 0.64 beat Data I/O's score of 0.50 indicating that Bionano Genomics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Data I/O
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bionano Genomics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Data I/O has higher earnings, but lower revenue than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Data I/O $21.50M 1.24 -$5.24M -$0.54 N/A
Bionano Genomics $28.51M 0.48 -$26.40M -$4.76 N/A
: 37.0% of Data I/O shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 7.3% of Data I/O shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Data I/O	-23.19%	-31.01%	-21.80%
Bionano Genomics	-92.59%	-56.22%	-34.38%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Data I/O	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Data I/O	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bionano Genomics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Data I/O	$21.50M	1.24	-$5.24M	-$0.54	N/A
Bionano Genomics	$28.51M	0.48	-$26.40M	-$4.76	N/A

Summary

Data I/O beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.

How does Bionano Genomics compare to MultiSensor AI?

MultiSensor AI (NASDAQ:MSAI) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

: MultiSensor AI has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
: Bionano Genomics has a net margin of -92.59% compared to MultiSensor AI's net margin of -211.01%. Bionano Genomics' return on equity of -56.22% beat MultiSensor AI's return on equity.
Company Net Margins Return on Equity Return on Assets
MultiSensor AI -211.01% -74.39% -59.77%
Bionano Genomics -92.59% -56.22% -34.38%
: In the previous week, Bionano Genomics had 3 more articles in the media than MultiSensor AI. MarketBeat recorded 4 mentions for Bionano Genomics and 1 mentions for MultiSensor AI. Bionano Genomics' average media sentiment score of 0.64 beat MultiSensor AI's score of 0.27 indicating that Bionano Genomics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MultiSensor AI
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bionano Genomics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 82.3% of MultiSensor AI shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 50.8% of MultiSensor AI shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: MultiSensor AI has higher earnings, but lower revenue than Bionano Genomics. MultiSensor AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MultiSensor AI $5.55M 2.28 -$11.71M -$12.80 N/A
Bionano Genomics $28.51M 0.48 -$26.40M -$4.76 N/A
: MultiSensor AI currently has a consensus target price of $120.00, indicating a potential upside of 1,804.76%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 383.87%. Given MultiSensor AI's stronger consensus rating and higher probable upside, equities analysts clearly believe MultiSensor AI is more favorable than Bionano Genomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MultiSensor AI
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
Bionano Genomics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Net Margins	Return on Equity	Return on Assets
MultiSensor AI	-211.01%	-74.39%	-59.77%
Bionano Genomics	-92.59%	-56.22%	-34.38%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MultiSensor AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bionano Genomics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MultiSensor AI	$5.55M	2.28	-$11.71M	-$12.80	N/A
Bionano Genomics	$28.51M	0.48	-$26.40M	-$4.76	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MultiSensor AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Bionano Genomics beats MultiSensor AI on 10 of the 17 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.75M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-0.26	38.92	29.03	28.47
Price / Sales	0.48	154.75	476.10	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	0.28	7.03	9.67	6.67
Net Income	-$26.40M	$23.62M	$3.55B	$332.53M
7 Day Performance	4.20%	3.78%	1.75%	2.03%
1 Month Performance	3.33%	7.30%	5.66%	9.23%
1 Year Performance	-68.61%	67.15%	34.42%	39.62%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	2.3265 of 5 stars	$1.24 flat	$6.00 +383.9%	N/A	$13.75M	$28.51M	N/A	300	News Coverage
PRPO Precipio	0.4007 of 5 stars	$30.70 +9.6%	N/A	N/A	$49.93M	$24.05M	N/A	60
AATC Autoscope Technologies	N/A	$5.35 -4.1%	N/A	N/A	$30.72M	$12.89M	6.08	40
CLIR ClearSign Technologies	3.9787 of 5 stars	$5.23 +4.6%	$20.00 +282.4%	N/A	$27.04M	$5.23M	N/A	10	Positive News Gap Down
DAIO Data I/O	2.4713 of 5 stars	$2.56 -6.6%	$5.11 +99.6%	N/A	$25.74M	$21.50M	N/A	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, AATC, CLIR, DAIO, and MSAI

How does Bionano Genomics compare to Precipio?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Summary

How does Bionano Genomics compare to Data I/O?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, AATC, CLIR, DAIO, and MSAI

How does Bionano Genomics compare to Precipio?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Summary

How does Bionano Genomics compare to Data I/O?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools